$PALI News

Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108

Palisade Bio Files Prospectus To Offer And Sell Up To $300M Of Securities

Palisade Bio Q1 EPS $(0.05) Misses $(0.04) Estimate

Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis

Palisade Bio Presents Additional Phase 1a/B Analyses Of PALI-2108, Including Delayed Ileocolonic Activation, High Tissue-To-Plasma Exposure, And Sustained Steady-State Concentrations Of Active Metabolite Above IC90, At Digestive Disease Week 2026

Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile

Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026

Palisade Bio's Data From Its Lead Program, PALI-2108, Selected For Poster Presentation At Digestive Disease Week 2026

Wolfe Research Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $7

Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference

TSX Penny Stocks To Watch In March 2026

Update: Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's Disease

Palisade Bio Shares Phase 1b PALI-2108 Data Showing Safety, PK and Early Crohn’s Efficacy Signals

Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease

Palisade Bio Announces Topline Data From Phase 1b Clinical Study Evaluating PALI-2108, Once-Daily Oral PDE4 Inhibitor Prodrug To Be Selectively Bioactivated In Ileum And Colon, In Patients With FSCD

HC Wainwright & Co. Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $7

Palisade Bio: Undervalued Biotech With Blockbuster Potential, Initiating With A Speculative Buy Rating

Palisade Bio (PALI) Reports Positive Phase 1b Data for PALI-2108 in UC Patients

Palisade Bio Announces Participation in Two Upcoming Investor Conferences

Stifel Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $5